Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
企業コードSTIM
会社名Neuronetics Inc
上場日Jun 28, 2018
最高経営責任者「CEO」Mr. Keith J. Sullivan
従業員数716
証券種類Ordinary Share
決算期末Jun 28
本社所在地3222 Phoenixville Pike
都市MALVERN
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号19355
電話番号18776007555
ウェブサイトhttps://neurostar.com/neuronetics/
企業コードSTIM
上場日Jun 28, 2018
最高経営責任者「CEO」Mr. Keith J. Sullivan
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし